Sample Submission Guidelines
The Critical Need for Organoid Genomic Validation
Patient-derived organoids (PDOs) have revolutionized disease modeling, personalized medicine, and precision oncology by preserving the three-dimensional architecture, cell-cell interactions, and functional characteristics of primary tissues. Unlike traditional 2D cell lines—which have spent decades adapting to flat plastic surfaces and often harbor genomes entirely alien to the original patient—PDOs are heralded as authentic "avatars" of the human disease state. However, visual morphology and expression of a few surface markers alone cannot guarantee that an organoid remains a faithful representation of the patient's disease at the molecular level.
Translational research relies heavily on the assumption that an organoid model mirrors the patient's in vivo tumor. Yet, the establishment of PDOs represents a significant evolutionary bottleneck. As organoids are established and passaged in vitro, they are continuously subjected to artificial selection pressures. The specific growth factors in the media (e.g., EGF, Noggin, R-spondin) may inadvertently favor the proliferation of wild-type epithelial cells over tumor cells, a phenomenon known as normal cell overgrowth. Alternatively, the culture conditions might select for a specific, fast-growing subclone that does not represent the bulk of the heterogeneous primary tumor.
Over time, minor subclones may drop out entirely, culture-induced genetic drift can occur, and critically, targetable driver mutations might be lost due to replicative stress and the absence of an intact immune system to clear aberrant cells.
Whole Exome Sequencing acts as the ultimate quality control (QC) gatepoint for your models. By profiling the entire coding region—which harbors the vast majority of known disease-causing and drug-targetable mutations—researchers can conclusively answer:
- Identity Confirmation: Does the organoid harbor the specific KRAS, TP53, PIK3CA, or EGFR driver mutations identified in the patient's clinical report?
- Clonal Heterogeneity: Are the minor subclonal populations from the primary tumor preserved in the 3D culture, or has the culture become monoclonal?
- Genomic Stability: Does the genomic profile drift significantly after 10, 20, or 30 passages?
- Absence of Artifacts: Have novel, hyper-proliferative mutations arisen in vitro that might confound results?
Without WES validation, researchers risk identifying drug sensitivities or resistance mechanisms that are artifacts of the culture system rather than true reflections of the patient's cancer biology. Millions of dollars in screening efforts can be wasted if the underlying model lacks the target of interest.
Matched Sample Study Design: The Triad Comparison
To confidently identify tumor-specific mutations, analyzing the organoid in isolation is wholly insufficient. We design whole exome sequencing projects around comparative relationships that accurately subtract inherited background noise.
When evaluating a patient-derived organoid, the gold-standard study design involves a three-component "Triad":
- Matched Normal Tissue (or Blood): Establishes the patient's baseline inherited germline variants. Since human genomes contain millions of benign inherited SNPs, a matched normal sample from the same patient is critical.
- Primary Tumor Tissue: Defines the original somatic mutation profile (the "ground truth" of the cancer) before any in vitro manipulation.
- Organoid Model: Represents the established in vitro culture being evaluated.
By sequencing all three components simultaneously, our advanced bioinformatics pipelines can accurately filter out germline variants. This prevents false-positive somatic mutation calls. For example, without a matched normal, a rare inherited SNP might be mistakenly classified as a novel tumor-specific driver. Our pipelines utilize complex statistical models (such as Bayesian somatic genotyping algorithms) to compare the allele frequencies between the normal, tumor, and organoid samples, ensuring that only true acquired mutations are reported.
If matched normal tissue is absolutely unavailable (which is common for commercially sourced biobank samples), we can employ tumor-only calling strategies. These strategies utilize massive population databases (e.g., dbSNP, gnomAD, 1000 Genomes Project) alongside panels of normals (PoN) to filter out common and rare germline variants. While effective, this approach inherently limits the absolute certainty of somatic variant confirmation compared to the Triad design.
Key Applications in Translational Research
Our Organoid WES services support a broad spectrum of advanced translational and preclinical research applications:
- Organoid Biobank Validation and Certification: Before distributing PDOs for large-scale studies or commercialization, biobanks must rigorously characterize their models. WES provides the standard genomic certification that a model accurately reflects the donor tissue.
- Pharmacogenomics and Drug Screening Correlations: WES allows researchers to correlate specific genomic alterations (e.g., Homologous Recombination Deficiency [HRD] mutations like BRCA1/2) with the organoid's response to targeted therapies (e.g., PARP inhibitors), ensuring the drug's mechanism of action matches the model's genotype.
- Modeling Acquired Therapeutic Resistance: By longitudinally sequencing organoids before treatment, during treatment, and after the emergence of resistance in vitro, researchers can identify newly acquired exonic mutations that confer drug resistance, mimicking clinical relapse.
- Tumor Evolution and Spatial Heterogeneity Studies: Researchers can perform multi-region sampling of a primary tumor and establish distinct organoid lines from those specific regions. WES mapping of these lines helps model spatial heterogeneity and clonal evolution in vitro.
- Preclinical "Avatar" Models for Co-Clinical Trials: In co-clinical trial setups, patient avatars (PDOs) are treated with drugs in parallel with the patient. WES confirms that the avatar retains the specific targetable mutations driving the patient's clinical response.
End-to-End WES Workflow for Organoids
Handling 3D organoid cultures requires specialized expertise to overcome unique challenges such as extracellular matrix (ECM) contamination, necrotic cores, and low cellular yields. Our laboratory workflow is heavily optimized to maximize data quality from limited and complex inputs.
Our comprehensive WES workflow includes critical QC checkpoints to ensure high-quality somatic variant calling from organoid models.
Sample Reception & Matrix-Free DNA Extraction:
- Accepts live organoids, frozen pellets, or pre-extracted genomic DNA.
- Complete removal of Matrigel, BME, or synthetic hydrogels is absolutely critical. Residual matrix proteins inhibit enzymatic reactions.
- QC Checkpoint: DNA concentration (Qubit), purity (NanoDrop), and integrity (DIN > 7 via TapeStation).
Advanced Library Preparation & Exome Capture:
- High-quality DNA is fragmented to 150-250 bp using acoustic shearing (Covaris) or enzymes.
- Adapters with unique dual indices (UDIs) are ligated to minimize index hopping.
- Hybridization to industry-leading exome capture probes (Agilent SureSelect XT HS2 or Twist Bioscience) targeting coding regions, UTRs, and flanking intronic sequences.
Ultra-Deep Sequencing Strategy:
- Sequenced on cutting-edge Illumina platforms (NovaSeq X Plus, PE150).
- 100X depth for normal samples, ≥200X to 500X depth for primary tumors and organoids.
- Deep sequencing ensures robust, statistically significant detection of rare subclones (VAF < 10%).
Advanced Triad Bioinformatics Analysis:
- Quality filtering and alignment to human reference genome (hg38) using BWA-MEM.
- Ensemble variant calling utilizing best-in-class algorithms (GATK Mutect2, Strelka2, VarScan2) for precision calling.
- Comprehensive functional annotation of SNVs and InDels.
If you are just starting your project, our organoid model development services can help coordinate the collection and banking of matched normal and tumor tissues alongside your organoids.
Specialized Bioinformatics Analysis for PDOs
We do not merely provide a raw list of mutations; we deliver a comparative analytical framework that directly answers whether your model is fit for your specific research purpose. Our bioinformatics deliverables are designed to be publication-ready.
Standard Pipeline Features
- Variant Annotation: Using ClinVar, COSMIC, dbNSFP, and SIFT/PolyPhen to predict functional impacts.
- Genomic Concordance Analysis: Jaccard similarity index calculations and Venn diagrams to quantify exact somatic overlap between the primary tumor and organoid.
- VAF Correlation Assessment: Scatter plots comparing Variant Allele Frequencies to reveal whether certain subclones were enriched or depleted during culture.
Optional Advanced Modules
- Mutational Signature Analysis: Extraction of COSMIC signatures to determine if fundamental mutational processes are maintained in vitro.
- Exome-Based CNV Inference: Utilizing tools like CNVkit or EXCAVATOR2 to infer targeted Copy Number Variations (e.g., HER2/ERBB2 amplifications or PTEN deletions) directly from WES coverage.
- TMB and MSI Scoring: Accurate estimation of Tumor Mutational Burden and Microsatellite Instability status directly from exome data.
- Mouse Read Subtraction (Xenograft Check): Utilizing in silico tools like Xenome to map reads to both human and mouse reference genomes, cleanly subtracting mouse DNA contamination from PDX-derived models.
For phenotypic integration, consider coupling this with our organoid characterization services.
Sample Requirements and Preparation Guidelines
Proper sample preparation dictates the ultimate success of library capture and sequencing. Organoids embedded in basement membrane extracts require careful handling to avoid downstream analytical failures. Furthermore, large organoids often develop necrotic cores that can release degraded DNA, negatively impacting library complexity.
| Sample Type | Minimum Input | Preparation & Shipping | Key Consideration |
|---|---|---|---|
| Genomic DNA | ≥ 500 ng | Ship on dry ice. EDTA-free buffer (e.g., 10mM Tris). | gDNA must show no significant degradation (DIN > 7). Avoid multiple freeze-thaw cycles. |
| Organoid Pellet | > 1×10^6 cells | Wash thoroughly with cold PBS or Cell Recovery Solution. Snap-freeze, ship on dry ice. | Incomplete matrix removal drastically inhibits cell lysis and extraction. For large organoids, gentle dissociation is recommended to wash away necrotic core debris. |
| Primary Tumor | > 10 mg tissue | Snap-freeze immediately after resection or biopsy. Ship on dry ice. | Tumor cellularity should be assessed histologically; high necrotic or stromal content reduces variant detection sensitivity. |
| Matched Normal | > 10 mg tissue or 2 mL blood | Snap-freeze normal adjacent tissue, or ship blood in EDTA tubes. | Essential for accurate somatic variant calling. Adjacent tissue must be histologically confirmed free of tumor infiltration. Blood is preferred. |
Strategy Selection: WES vs. WGS vs. RNA-Seq vs. Targeted Panels
Selecting the correct sequencing modality ensures you answer your biological question without overspending your grant or budget.
- Whole Exome Sequencing (WES): Best for discovering and validating coding-region somatic mutations (SNVs and InDels), confirming driver mutations, identifying novel coding mutations, and tracking clonal evolution at high depth. Highly cost-effective for large biobanks. Not for identifying large structural variations in non-coding regions.
- Whole Genome Sequencing (WGS): Best for comprehensive mapping of the entire genome including deep intronic and regulatory elements. Not for routine high-throughput validation on a budget, due to the high cost of 200X to 500X coverage across the whole genome.
- Targeted Gene Panels: Best for ultra-deep sequencing (1000X+) of a small, predefined set of known cancer genes to track specific known drivers. Not for discovering novel mutations outside the panel or comprehensively assessing overall genomic drift.
- Transcriptome Sequencing (RNA-Seq): Best for measuring active gene expression and identifying fusions via our organoid research solutions. Not for accurately calling DNA-level mutations due to RNA editing, nonsense-mediated decay, and massive expression bias.
References:
- Luo Z, Wang B, Luo F, et al. Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening. BMC Medicine. 2023;21:336. https://doi.org/10.1186/s12916-023-03034-y
- Ahn S-J, Lee S, Kwon D, et al. Essential Guidelines for Manufacturing and Application of Organoids. International Journal of Stem Cells. 2024;17(2):102-112. https://doi.org/10.15283/ijsc24047
For research use only. Not for use in diagnostic procedures, clinical decision-making, patient stratification, therapeutic selection, or clinical trials.
Illustrative Result Formats
The following planned visuals explain common deliverable structures provided in our organoid genomic fidelity reports. They are illustrative examples demonstrating data formats, not actual patient data.
Somatic Mutation Overlap Analysis
A foundational requirement for organoid validation is demonstrating exactly how many somatic mutations are shared. A three-way Venn diagram clearly illustrates the intersection of variants called in the Primary Tumor, the Organoid Model, and the Matched Normal. A high-fidelity model shows a substantial overlap of tumor-specific somatic mutations, with very few "Organoid-Unique" variants (indicating minimal culture-induced drift).
Variant Allele Frequency Correlation
Maintaining the proportion of cells carrying a mutation is crucial for preserving tumor heterogeneity. A VAF Scatter Plot maps the frequency of each mutation in the primary tumor against its frequency in the organoid. Mutations falling along the diagonal indicate perfect clonal preservation. Variants deviating heavily toward the Y-axis represent minor subclones that rapidly expanded during in vitro culture.
Mutational Signature Profiling
Cancer genomes are shaped by underlying mutational processes. By analyzing the frequency of 96 possible trinucleotide context changes, we extract established COSMIC mutational signatures from the exome data. Comparing the signature profile of the tumor to the organoid confirms whether fundamental biological drivers of genomic instability (e.g., HRD, mismatch repair defects) remain active in the 3D model.
Organoid WES FAQs
1. Why is matched normal tissue so critical? Can't you just use dbSNP?
While population databases like dbSNP, gnomAD, and the 1000 Genomes Project contain millions of common human variants, they do not contain every private, rare, or family-specific inherited mutation. Without a matched normal sample (like blood or healthy adjacent tissue) from the specific patient, it is nearly impossible to definitively prove that a novel variant found in the organoid is a true acquired somatic tumor mutation rather than a rare inherited germline trait.
2. How deep should I sequence my organoids?
For standard germline analysis, 100X depth is typically sufficient. However, tumors and their derived organoids are highly heterogeneous. A critical driver mutation or a rare drug-resistant subclone might only be present in 5% of the cells. To reliably detect these low-frequency subclonal variants (VAF < 10%) with statistical confidence, we strongly recommend sequencing the tumor and organoid samples to a depth of 200X to 500X.
3. Does Matrigel interfere with WES?
Yes. Matrigel and other basement membrane extracts are protein-rich extracellular matrices that can trap cells, block lysis buffers, and inhibit the enzymes used during DNA extraction and library preparation. Organoids must be carefully recovered from the matrix using cold PBS washes or specialized cell recovery solutions (like Corning Cell Recovery Solution) before pelleting and freezing to ensure high DNA yield and quality.
4. Can WES detect Copy Number Variations (CNVs) and Gene Amplifications?
WES is primarily designed for detecting small variants (SNPs and InDels) in coding regions. However, through specialized bioinformatics tools (like CNVkit or EXCAVATOR), we can infer targeted CNVs by comparing read depth coverage across targeted exons between the tumor/organoid and the normal sample. This is highly effective for detecting massive amplifications (e.g., HER2 amplification in breast organoids). Note that WES cannot reliably map structural variant breakpoints or large-scale rearrangements in non-coding regions; Whole Genome Sequencing (WGS) is required for those applications.
5. How many passages is too many? When should I re-sequence my organoids?
Genomic stability varies wildly depending on the tissue origin, the specific mutations present (e.g., mismatch repair deficient tumors drift much faster), and the selective pressures of the culture media. Generally, organoids are considered "early passage" and most stable between passages 1 to 10. We recommend sequencing early-passage organoids for initial validation, and performing periodic re-sequencing (e.g., every 10-15 passages) if the model is maintained in long-term continuous culture to monitor for genetic drift.
6. Do you support mouse or other non-human organoids?
Yes. While human PDOs are the most common, our WES services and exome capture kits are fully compatible with mouse-derived organoids (murine models), canine models, and other widely studied mammalian species. Please consult our team regarding the specific reference genomes and capture kits available for your species of interest.
7. Can I submit FFPE primary tumor samples to compare with my live organoids?
Yes, we accept Formalin-Fixed Paraffin-Embedded (FFPE) tissue. However, formalin fixation causes DNA cross-linking, severe fragmentation, and introduces sequencing artifacts (specifically C>T transitions caused by cytosine deamination). We employ specialized FFPE DNA extraction and enzymatic repair protocols (e.g., UDG treatment) to mitigate this, but fresh-frozen tissue is always highly preferred when available for the highest quality comparison.
8. What format is the data delivered in, and how long does it take?
Turnaround time is project-dependent based on sample volume, preparation requirements, and sequencing depth. Data is delivered securely via cloud download or physical hard drive. You will receive raw FASTQ files, aligned BAM files, annotated VCFs, and a comprehensive PDF bioinformatics report containing all QC metrics, tables, and visual plots.
9. Can WES data be used to design custom targeted panels for downstream screening?
Absolutely. Many researchers use our WES services on the primary tumor and early-passage organoid to discover the specific patient-derived somatic mutations. We can then use that data to help design an ultra-targeted, custom Amplicon or Capture panel (e.g., 50 specific mutations). You can then use this much cheaper custom panel to rapidly screen hundreds of downstream organoid clones or track mutations over time during drug treatment.
10. How do you handle mouse cell contamination if my organoid was derived from a PDX model?
Organoids established from Patient-Derived Xenografts (PDX) often carry over mouse stromal cells. If sequenced directly, mouse DNA will map ambiguously to the human genome, causing massive false-positive variant calls. We utilize specialized in silico tools (such as Xenome) to map all sequencing reads to both human and mouse reference genomes simultaneously. We unambiguously identify and discard the mouse reads, ensuring variant calling is performed exclusively on the human organoid DNA.
Case Studies: Validating Genomic Fidelity for High-Throughput Applications
Case Study 1: Validating a Colorectal Adenoma Organoid Biobank
Background
The establishment of large-scale biobanks is critical for high-throughput pharmacological testing. However, before a biobank can be deemed reliable for drug screening, the in vitro models must be rigorously validated to ensure they recapitulate the genetic landscape of the original patient tissues. In a comprehensive 2023 study, researchers aimed to build a living biobank of high-risk colorectal adenoma organoids to study cancer predisposition and drug response.
Methodology
To prove the fidelity of their models, the researchers isolated genomic DNA from the primary adenoma tissues, the corresponding early-passage organoids, and matched normal patient tissue (to serve as the germline control). They performed Whole Exome Sequencing (WES) using a matched Triad design. Sequencing was performed at a high depth to ensure even rare subclonal variants were detected. The bioinformatics pipeline utilized GATK Best Practices for germline filtering, followed by somatic variant calling to identify specific SNPs and InDels.
Results
The comparative WES data revealed a striking genomic concordance. The organoids faithfully retained the vast majority of somatic mutations present in the parental adenomas. Crucially, specific cancer-predisposing driver mutations in the Wnt/β-catenin pathway (e.g., APC mutations) and the PI3K/AKT pathway were perfectly preserved in the in vitro cultures. Furthermore, by calculating the mutational burden and comparing Variant Allele Frequencies (VAFs), the team demonstrated that the clonal architecture of the adenomas remained highly stable across initial passaging, with no significant accumulation of culture-induced artifacts.
Conclusion
By anchoring their model validation with high-depth WES, the research team definitively proved that their colorectal adenoma organoids were genetically accurate representations of the primary disease. This genomic certification allowed them to confidently proceed to high-throughput and high-content drug screening, knowing their results would be biologically relevant to patient pathology.
Independent research characterizing patient-derived adenoma organoids. Adapted from Luo Z, et al. (2023), BMC Medicine. Source: Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank... The published study was independent of CD Genomics.
Case Study 2: Tracking Clonal Dynamics in Pancreatic Ductal Adenocarcinoma (PDAC) Organoids
Background: Pancreatic Ductal Adenocarcinoma (PDAC) is notorious for its dense stroma and complex mutational landscape. Researchers developing PDAC organoids frequently struggle to confirm whether their cultures represent the actual malignant epithelial cells or merely normal ductal cells that outcompeted the tumor cells in vitro.
Methodology: A research group submitted patient-matched Triad samples (Blood, PDAC Primary Tumor, and Passage 5 Organoids) to CD Genomics for high-depth WES (300X coverage). The goal was to confirm malignant identity and assess whether the KRAS and SMAD4 mutations identified in the patient's clinical biopsy were retained.
Results: The WES pipeline successfully filtered out over 40,000 inherited germline variants. Somatic variant calling identified the exact KRAS G12D driver mutation in the organoid model. Interestingly, VAF correlation analysis revealed that a minor subclone carrying a SMAD4 deletion (present at only 8% VAF in the primary tumor) had expanded to 65% VAF in the organoid culture, indicating a strong in vitro selection advantage for this specific subpopulation.
Conclusion: WES not only certified the malignant identity of the PDAC organoid (proving it was not a normal tissue outgrowth), but the deep subclonal analysis revealed dynamic clonal expansion. The researchers were able to adjust their drug screening interpretation, knowing their model was heavily enriched for the SMAD4-deficient subclone.